Bachem Overview
- Year Founded
-
1971
- Status
-
Public
- Employees
-
2,725
- Stock Symbol
-
BANB
- Investments
-
9
- Share Price
-
$96.83
- (As of Thursday Closing)
Bachem General Information
Description
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
Contact Information
Website
www.bachem.comCorporate Office
- Hauptstrasse 144
- 4416 Bubendorf
- Switzerland
Corporate Office
- Hauptstrasse 144
- 4416 Bubendorf
- Switzerland
Bachem Stock Performance
As of 12-Nov-2026, Bachem’s stock price is $96.83. Its current market cap is $7.26B with 74.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $96.83 | $97.92 | $60.43 - $106.87 | $7.26B | 74.9M | 89.3K | $2.49 |
Bachem Financials Summary
As of 30-Jun-2026, Bachem has a trailing 12-month revenue of $893M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,049,745 | 5,731,870 | 4,621,035 | 5,435,561 |
| Revenue | 892,781 | 836,315 | 687,396 | 642,233 |
| EBITDA | 274,237 | 245,433 | 201,458 | 177,893 |
| Net Income | 187,699 | 179,029 | 136,566 | 124,437 |
| Total Assets | 2,895,465 | 2,662,801 | 2,128,287 | 2,003,572 |
| Total Debt | 257,595 | 72,472 | 321 | 477 |
Bachem Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bachem Comparisons
Industry
Financing
Details
Bachem Competitors (3)
One of Bachem’s 3 competitors is Lonza Group, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lonza Group | Corporation | Basel, Switzerland | ||||
| GenScript | Formerly VC-backed | Nanjing, China | ||||
| AnaSpec | Corporate Backed or Acquired | Fremont, CA |
Bachem Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bachem Patents
Bachem Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026124814-A1 | Trichloroacetic acid based cleavage reagent for peptide synthesis | Pending | 12-Dec-2024 | ||
| US-20260035406-A1 | Synthesis of glp-1r/gipr agonists | Pending | 31-Jul-2024 | ||
| WO-2025229200-A1 | Manufacture of disulfide bonded peptides | Pending | 03-May-2024 | ||
| GB-202504212-D0 | Solid-phase synthesis in a aqueous solution | Pending | 21-Mar-2024 | ||
| GB-2700631-A | Solid-phase synthesis in a aqueous solution | Pending | 21-Mar-2024 | C07K7/06 |
Bachem Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bachem Investments & Acquisitions (9)
Bachem’s most recent deal was a Merger/Acquisition with Peptidences Pharma. The deal was made on 23-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Peptidences Pharma | 23-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| Bachem Holding (Property in Vista, California) | 23-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Ingro Immobilien | 25-Apr-2022 | Merger/Acquisition | Other Financial Services | ||
| Synprosis | 01-Apr-2022 | Merger/Acquisition | Drug Discovery | ||
| American Peptide | 27-Mar-2015 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Bachem ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
20.47 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Bachem Exits (2)
Bachem’s most recent exit was on 13-Aug-2007 from Pevion Biotech. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pevion Biotech | 13-Aug-2007 | Completed |
|
||
| Pevion Biotech | 15-Jan-2002 | Joint Venture | Completed |
|
Bachem Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Peptidences Pharma | Dallas, TX | 2024 |
Bachem FAQs
-
When was Bachem founded?
Bachem was founded in 1971.
-
Where is Bachem headquartered?
Bachem is headquartered in Bubendorf, Switzerland.
-
What is the size of Bachem?
Bachem has 2,725 total employees.
-
What industry is Bachem in?
Bachem’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Bachem a private or public company?
Bachem is a Public company.
-
What is Bachem’s stock symbol?
The ticker symbol for Bachem is BANB.
-
What is the current stock price of Bachem?
As of 12-Nov-2026 the stock price of Bachem is $96.83.
-
What is the current market cap of Bachem?
The current market capitalization of Bachem is $7.26B.
-
What is Bachem’s current revenue?
The trailing twelve month revenue for Bachem is $893M.
-
Who are Bachem’s competitors?
Lonza Group, GenScript, and AnaSpec are competitors of Bachem.
-
What is Bachem’s annual earnings per share (EPS)?
Bachem’s EPS for 12 months was $2.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
